Notice of Intent to Sole Source – Illumina
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
NATIONAL INSTITUTES OF HEALTH OLAO
Contract Value
Not provided
Codes & Classification
Solicitation Number
26-005075
NAICS
339112 - Surgical and Medical Instrument Manufacturing
Classification Code
6515
Additional Details
The National Institutes of Health (NIH), through its Office of Logistics and Acquisition Operations (OLAO), has issued a Special Notice indicating its intent to award a sole source, firm fixed price purchase order to Illumina, Inc. This procurement is for a maintenance agreement covering the Illumina NextSeq 1000 Sequencing System, which is currently in use at the Department of Transfusion Medicine (DTM) within the NIH Clinical Center, located in Bethesda, Maryland.
The primary objective of this acquisition is to ensure the continued optimal performance and reliability of the Illumina NextSeq 1000 Sequencing System, a critical piece of medical laboratory equipment used in advanced sequencing applications. The maintenance agreement will provide essential support services, including manufacturer-authorized servicing and parts, to minimize downtime and maintain the integrity of ongoing research and clinical operations at the DTM.
This procurement is classified under Product Service Code 6515 (Medical Instruments, Equipment, and Supplies) and North American Industry Classification System (NAICS) code 339112 (Surgical and Medical Instrument Manufacturing). The place of performance is Bethesda, MD 20892, United States.
The NIH has determined that Illumina, Inc., as the original equipment manufacturer (OEM) of the NextSeq 1000 Sequencing System, is the only source capable of providing the required maintenance services. The equipment is both manufactured and serviced exclusively by Illumina, and procuring maintenance from the OEM is deemed to be in the best interest of the Government to ensure compatibility, maintain warranties, and uphold performance standards.
This action is being conducted in accordance with Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, specifically Subpart 13.106-1(b)(1), which allows for sole source awards when only one source is reasonably available and the acquisition does not exceed the simplified acquisition threshold. As such, this procurement is exempt from the competition requirements outlined in FAR Part 6.
No set-aside applies to this procurement; it is not restricted to small businesses or any other socioeconomic category. Interested parties who believe they can fulfill the requirement are invited to submit their capabilities and expressions of interest. However, the Government reserves the right to proceed with the sole source award at its discretion, based on the responses received.
The notice is not a request for quotations or proposals, and no solicitation document will be issued. Comments or capability statements referencing this posting number may be submitted to the NIH Clinical Center, Office of Purchasing and Contracts, directed to Gregory Noland, Contract Specialist, via email at [email protected] by May 10, 2026, at 16:00 EST.
For further information, interested parties may refer to the official notice on SAM.gov (Opportunity ID: a40cb9e65b1e449cb46667c892b9a7e0) or contact Gregory Noland at 301-827-3078.
This notice remains active as of its posting date, April 5, 2026.